Skip to main content

Table 3 Outcomes of infective endocarditis

From: DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

 

IE type

Micro-organism

Reason for surgery

Before-DBV treatment (weeks)

Reasons for DBV prescription

Adverse effects

Cure of infection

DBV dose (mg)

1

LPVE

MSSA

Yes (1)

1st. Vancomycin (< 1), and cloxacillin (2); 2nd. surgery; 3rd. cloxacillin (2) plus fosfomycin (2)

Outpatient management

No

Yes

1000 (1 day)

500 (8 days)

2

EPVE

S. epidermidis

Yes (1)

1st. Daptomycin (< 1) plus rifampicin (< 1); 2nd. vancomycin (2) plus rifampin (2); 3rd. surgery; 4th. vancomycin plus rifampicin (2)

Outpatient management

No

Yes

1000 (1 day)

500 (8 days)

3

EPVE

MRSA

 

1st. Vancomycin (< 1); 2nd. daptomycin (3) plus fosfomycin (3)

Outpatient management

Yes (fever)

Yes

1000 (1 day)

500 (8 days)

500 (15 days)

4

PLE

S. epidermidis

Yes (2)

1st. Amoxicillin-clavulanic acid (< 1); 2nd. linezolid (3); 3rd. surgery; 4th. daptomycin (4)

Outpatient management

No

Yes

1500 (1 day)

5

NVE

S. agalactiae

Yes (3)

1st. Vancomycin (< 1); 2nd. penicillin G (3) plus gentamycin (3); 3rd. surgery; 4th. ceftriaxone (1)

Outpatient management

No

Yes

1500 (1)

6

LPVE

S. epidermidis.

 

1st. Moxifloxacin (< 1); 2nd. daptomycin (1), cloxacillin (1) plus gentamycin (1), plus rifampicin (1); 3rd. daptomycin (6)

Outpatient management

No

Yes

Death not-related with IE (6 months later)

1000 (1 day)

500 (8 days)

7

NVE

MSSA

 

1st. Daptomycin (1) plus gentamycin (1); 2nd. cloxacillin (3) plus gentamycin (1)

Outpatient management

No

Loss to follow up

1000(1 day)

8

NVE

Unknown

 

1st. Ceftriaxone (< 1); 2nd daptomycin (< 1); 3rd. imipenem/cilastatin (1)

Outpatient management

No

Yes

1500 (1 day)

1000 (15 days)

9

LPVE

S. epidermidis.

 

1st. Cloxacillin (< 1) plus daptomycin (< 1); 2nd. daptomycin (3) plus gentamycin (2) plus fosfomycin (2)

Previous treatment failure

No

Yes

1500 (1 day)

10

PLE

S. epidermidis.

Yes (4)

1st. Daptomycin (1), gentamycin (1), rifampicin (1), 2nd. surgery

Outpatient management

Yes (renal failure)

Treatment failure

1500 (1 day)

11

NVE

S. agalactiae

 

1st. Ertapenem (< 1); 2nd. ampicillin (1) plus gentamycin (1); 3rd. ceftriaxone (1)

Outpatient management

No

Yes

1500 (1 day)

500 (8 days)

12

NVE

E. faecalis

 

1st. Meropenem (< 1); 2nd. ampicillin (3) plus ceftriaxone (3); 3rd. linezolid (1); 4th. daptomycin (2)

Outpatient management

No

Yes

1000 (1 day)

13

NVE

S. lugdunensis

Yes (1)

1st. Cloxacillin (3); 2nd. surgery; 3rd daptomycin (1)

Outpatient management

No

Yes

1500 (1 day)

14

EPVE

CNS

Yes (1)

1st. Aztreonam (< 1); 2nd. daptomycin (2) plus rifampicin (2) plus fosfomycin (2); 3rd. surgery; 4th. daptomycin (2) plus rifampicin (4) plus fosfomycin (4)

Outpatient management

No

Yes

1500 (1 day)

15

LPVE

MSSA

 

1st. Piperacillin/tazobactam (1); 2nd. cloxacillin (1) plus daptomycin (1) plus rifampicin (1); 3rd. cloxacillin (2) plus rifampicin (2) plus fosfomycin (< 1)

Outpatient management

No

Yes

1000 (1 day)

16

NVE

S. viridans

 

1st. Amoxicillin-clavulanate (1); 2nd. ceftriaxone (3)

Outpatient management

No

Yes

1500 (1 day)

17

PLE

S. epidermidis

Yes (4)

1st. Cloxacillin (< 1) plus gentamycin (< 1) plus rifampicin (1); 2nd. surgery; 3rd. daptomycin (2)

Outpatient management

No

Yes

1500 (1 day)

18

PLE

S. epidermidis

Yes (4)

1st. Rifampicin (1), gentamycin (1), daptomycin (1); 2nd. surgery

Outpatient management

No

Yes

1500 (1 day)

19

PLE

S. schleiferi

Yes (4)

1st. Ceftriaxone (< 1); 2nd. surgery; 3rd. cloxacillin (2)

Outpatient management

No

Yes

1000 (1 day)

500 (8 days)

20

PLE

S. epidermidis

Yes (4)

1st. Meropenem (< 1); 2nd. surgery; 3rd. daptomycin (2)

Outpatient management

No

Yes

1000 (1 day)

21

NVE

MSSA

Yes (1)

1st. Ceftriaxone (< 1), 2nd. daptomycin (< 1) plus gentamycin (1); 3rd. cloxacillin (1); 4th. Surgery; 5th. cloxacillin (2) plus rifampicin (1)

Outpatient management

No

Yes

1500 (1 day)

22

EPVE

MRSA

Yes (1)

1st. Daptomycin (2), gentamycin (2), rifampicin (2); 2nd. surgery; 3rd daptomycin (1)

Previous treatment failure

No

Yes

1500 (1 day)

1000 (15 days)

23

NVE

E. faecalis

 

1st. Ampicillin plus ceftriaxone (4)

Outpatient management

No

Yes

1000 (1)

500 (8 days)

24

NVE

MSSA

 

1st. Ceftriaxone (< 1) plus levofloxacin (< 1); 2nd. cloxacillin (1); 3rd. cefazolin (1)

Outpatient management

No

Yes

Death not-related with IE (3 months later)

1000 (1 day)

25

PLE

CNS

Yes (5)

1st. Daptomycin (1), gentamycin (1), rifampicin (1); 2nd. surgery; 3rd. daptomycin (1)

Outpatient management

No

Yes

1000 (1 day)

5002 (8 days)

26

PLE

CNS

Yes (6)

1st. Levofloxacin (2); 2nd. daptomycin (2); 3rd. surgery; 4th. daptomycin (2)

Outpatient management

No

Yes

1000 (1 day)

500 (8 days)

27

LPVE

MSSA

 

1st. Vancomycin (< 1) plus gentamycin (< 1) plus rifampin (< 1), 2nd. daptomycin (1) plus rifampicin (1); 3rd. cloxacillin (2) plus rifampicin (2)

Outpatient management

No

Yes

1000 (1 day)

500 (8 days)

28

LPVE

MRSA

 

1st. Vancomycin (2), 2nd. linezolid (1); 3rd. ceftaroline (4)

Previous treatment failure

No

Yes

1000 (1 day)

500 mg/every week/9 weeks

29

LPVE

S. bovis

 

1st. Vancomycin (< 1) plus rifampicin (< 1) plus gentamycin (< 1), 2nd. ceftriaxone (4) plus gentamycin (4)

Outpatient management

No

Yes

Death not-related with IE (4 months later)

1500 (1 day)

1000/every 2 weeks/10 weeks

30

LPVE

S. lugdunensis

 

1st ceftriaxone (< 1); 2nd cloxacillin (2)

Outpatient management

No

Yes

1000 (1 day)

500 (8 days)

31

NVE

MR S. epidermidis

 

1st. Daptomycin (4)

Outpatient management

No

Yes

1000 (1 day)

500 (8 days)

32

EPVE

MSSA

 

1st. Levofloxacin (< 1), 2nd. daptomycin (< 1), 3rd. cloxacillin (4) plus rifampicin (3) plus gentamycin (2)

Outpatient management

No

Yes

1500 (1 day)

33

LPVE

E. faecalis

Yes (1)

1st. Vancomycin (2), gentamycin (< 1); 2nd. surgery; 3rd. vancomycin (1)

Outpatient management

No

Yes

1500 (1 day)

1000 (15 days)

1000 (30 days)

1000 (45 days)

34

LPVE

S. epidermidis

Yes (1)

1st. Daptomycin (2) plus rifampicin (2); 2nd. surgery; 3rd. daptomycin (2)

Outpatient management

No

Yes

1500 (1 day)

  1. MSSA: methicillin-sensitive S. aureus; MRSA: methicillin-resistant S. aureus; CNS: coagulase negative staphylococcus; LPVE late prosthetic valve endocarditis; NVE native valve endocarditis; EPVE early prosthetic valve endocarditis; PLE pacemaker lead endocarditis
  2. (1) Aortic or mitral valve replacement. (2) Electrode removal. (3) Mitral valve repair with ring. (4) Electrode and pacemaker lead removal. (5) Pacemaker removal and pus drainage from pocket. (6) Pacemaker lead removal without removing electrode from the implantable automatic defibrillator